Omega-3 Fish Oil: Benefits, Dosage and What the Trials Found

Omega-3 fatty acids are among the most studied nutrients in modern medicine. Thousands of clinical trials have examined their effects on everything from heart disease to depression, and the evidence paints a nuanced picture. Some benefits are backed by large-scale trials involving tens of thousands of patients, while others rest on smaller studies with mixed results.

This guide cuts through the marketing claims to examine what the clinical research actually supports. We cover the distinct roles of EPA and DHA, the specific conditions where omega-3 supplementation has the strongest evidence, recommended dosages for different health goals, and how to choose the right form of omega-3 for your needs.

EPA vs DHA: Two Fatty Acids, Different Jobs

Most omega-3 supplements contain both EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), but these two fatty acids have distinct biological roles that matter when choosing a supplement for a specific health goal.

EPA is primarily an anti-inflammatory agent. It competes with arachidonic acid in inflammatory pathways, reducing the production of pro-inflammatory prostaglandins and leukotrienes. EPA is the fatty acid most strongly linked to benefits in joint inflammation, depression and cardiovascular risk reduction. Clinical trials on depression consistently show that formulations containing at least 60% EPA produce the best outcomes.

DHA is primarily a structural component. It makes up 97% of the omega-3 fatty acids in the brain and 93% in the retina. DHA is critical for brain development during pregnancy and early life, and plays a key role in maintaining cell membrane fluidity throughout the body. Research shows DHA has a stronger effect on lowering blood pressure than EPA and is more potent at reducing the genetic expression of pro-inflammatory proteins.

Understanding this distinction helps you match your supplement choice to your health priorities. For joint pain and mood support, look for higher EPA. For brain health and pregnancy, prioritise DHA. For general health maintenance, a balanced EPA/DHA combination covers both bases.

Heart Health: The Largest Evidence Base

Cardiovascular health is where omega-3 research began, and it remains the area with the most extensive clinical trial data spanning decades of investigation.

The landmark GISSI-Prevenzione trial enrolled 11,324 patients who had recently suffered a heart attack and randomised them to receive either 1g of omega-3 daily or standard care. Over 3.5 years, the omega-3 group showed a significant reduction in death and the combined endpoint of death, non-fatal heart attack and stroke (Marchioli et al., 1999). This trial established the foundation for omega-3 in cardiac care.

More recently, the REDUCE-IT trial tested high-dose icosapent ethyl (a purified EPA derivative) at 4g daily in 8,179 statin-treated patients with elevated triglycerides. The results showed a significant reduction in major cardiovascular events including cardiovascular death, heart attack, stroke and unstable angina (Bhatt et al., 2019). This trial was notable because it used pure EPA rather than an EPA/DHA combination.

However, not all large trials have been positive. The STRENGTH trial of 13,078 participants found no cardiovascular benefit from omega-3 carboxylic acid (an EPA/DHA combination) compared to corn oil, and noted increased atrial fibrillation in the omega-3 group. This divergence between EPA-only and EPA/DHA combination results has shaped current clinical thinking, with pure EPA showing more consistent cardiovascular benefits.

For triglyceride reduction specifically, doses of 3-4g per day of combined EPA and DHA can achieve a 20-50% reduction in individuals with triglycerides above 150 mg/dL. This is a well-established effect acknowledged even by researchers who question other cardiovascular claims.

Joint Health and Rheumatoid Arthritis

The evidence for omega-3 in joint health depends heavily on which type of arthritis you have. For rheumatoid arthritis, the data is strong. For osteoarthritis, it is considerably weaker and should be stated honestly.

A 2024 meta-analysis of 18 randomised controlled trials involving 1,018 rheumatoid arthritis patients found that omega-3 supplementation significantly reduced tender joint count by a rate difference of -2.9 at three months. Across 20 clinical trials, 16 demonstrated significant improvements in multiple disease outcomes. At dosages above 2.6g per day, omega-3 reduced the need for anti-rheumatic medication in some patients.

The pioneering work by Kremer et al. in the 1990s demonstrated dose-dependent improvements in RA disease markers. In a study of 66 RA patients taking 130mg/kg/day of omega-3, significant improvements were observed in tender joint counts, morning stiffness duration and pain assessments compared to corn oil placebo (Kremer et al., 1995).

For osteoarthritis, the evidence is less convincing. A meta-analysis of 4 clinical trials found that omega-3 benefits for OA were not statistically significant. If you have osteoarthritis, supplements like curcumin and green lipped mussel have stronger evidence for pain relief. Our complete arthritis supplements guide ranks the evidence for each option.

Brain Health and Cognitive Function

The brain is roughly 60% fat by dry weight, and DHA is its most abundant omega-3 fatty acid. This basic biology has driven extensive research into whether omega-3 supplementation can protect or improve cognitive function across the lifespan.

A comprehensive meta-analysis of 78 randomised controlled trials found that 43.6% reported positive cognitive outcomes with omega-3 compared to placebo. The optimal dose range was identified as 1,000-2,500mg per day, with each additional 2,000mg showing significant improvement in attention and perceptual speed. The benefits were clearest in people with mild cognitive impairment, where 66.7% of trials showed positive outcomes.

Neuroimaging studies have revealed that EPA and DHA affect the brain differently. In a crossover trial of 30 healthy participants, EPA-rich supplementation produced faster reaction times on cognitive tasks, while DHA-rich supplementation changed brain activation patterns without measurable behavioural improvement. This suggests EPA may have more immediate cognitive effects, while DHA supports longer-term brain structure.

One important genetic factor: individuals carrying the ApoE4 allele, which increases Alzheimer's disease risk, may be less likely to benefit from DHA supplementation. This is an emerging area of personalised nutrition where genetic testing could inform supplement choices in the future.

For cognitively healthy adults over 55, the evidence is genuinely mixed, with roughly half of trials showing benefit and half showing none. The strongest case for omega-3 and brain health is in early cognitive decline rather than prevention in healthy individuals.

Depression and Anxiety

Mental health is one of the more compelling areas for omega-3 research, particularly when EPA-enriched formulations are used as an adjunct to standard antidepressant treatment rather than a replacement.

A landmark study by Nemets et al. (2002) tested EPA added to ongoing antidepressant therapy in 20 patients with recurrent major depressive disorder. The results showed highly significant benefits by week three compared to placebo. This small but influential trial helped establish the principle that EPA-enriched omega-3 can enhance the effectiveness of conventional antidepressants.

A meta-analysis of 26 studies with 2,160 participants confirmed an overall beneficial effect. However, the detail matters enormously. EPA-enriched interventions (at least 60% EPA of total EPA/DHA) at doses of 1-2g per day showed clear benefits. Critically, EPA doses above 2g per day were not associated with therapeutic effects, suggesting a specific therapeutic window rather than a "more is better" relationship.

For anxiety, a 2024 meta-analysis of 23 trials with 2,189 participants found that each 1g per day of omega-3 produced a moderate decrease in anxiety symptoms. The optimal dose was 2g per day, beyond which no additional benefit was observed. The effect was consistent enough to suggest omega-3 as a worthwhile adjunct for anxiety management.

These findings do not mean omega-3 replaces mental health treatment. They mean that for people already managing depression or anxiety, omega-3 supplementation with an EPA-dominant formula can provide additional support that the clinical evidence actually backs up.

Skin Health: Psoriasis and Eczema

Omega-3 fatty acids influence skin health through their anti-inflammatory effects and their role in maintaining the skin's lipid barrier. The clinical evidence is strongest for inflammatory skin conditions rather than general skin appearance.

For psoriasis, a meta-analysis of 10 studies covering 560 participants found a significant reduction in PASI scores (the standard measure of psoriasis severity) of -1.58 (p<0.001). A dedicated trial using herring roe oil at 2,600mg EPA/DHA daily for 26 weeks confirmed measurable improvement in plaque psoriasis compared to placebo.

For atopic dermatitis (eczema), Koch et al. conducted an 8-week randomised trial in 53 patients using high-dose DHA (5.4g/day) and found significant improvement in dermatitis severity scores. Notably, eczema research points more toward DHA than EPA, which makes sense given DHA's role in cell membrane structure and skin barrier function.

A broader review of 38 studies reported benefits for psoriasis, atopic dermatitis, acne and skin ulcers. While the evidence is not as strong as for cardiovascular or joint health, omega-3 supplementation at adequate doses appears to offer genuine support for people with inflammatory skin conditions. Our collagen supplement range complements omega-3 for skin health by providing the structural building blocks for skin repair.

EPA and DHA: Matching Your Supplement to Your Goal

How Much Omega-3 Do You Actually Need?

Recommended omega-3 intake varies significantly depending on whether you are following general health guidelines or targeting a specific condition with therapeutic doses.

The World Health Organisation recommends 250-500mg of combined EPA and DHA daily for general health. The UK NHS advises eating at least two portions of fish per week, including one portion of oily fish (salmon, mackerel, sardines), which provides roughly 1-2g of long-chain omega-3 per serving. The European Food Safety Authority considers up to 5g per day of combined EPA and DHA as safe, though the NHS suggests not exceeding 3g from supplements without medical supervision.

The gap between general guidelines and therapeutic doses is significant. The WHO minimum of 250mg covers basic health maintenance, but the clinical evidence for specific conditions starts at 1g daily and often requires 2-4g for meaningful results. If you are supplementing for a specific health reason, the dose needs to match the evidence for that condition, not just the general population minimum. Pairing omega-3 with vitamin D3 is a common complementary strategy, as both nutrients support immune function and inflammation management.

Omega-3 supplements are generally well tolerated. The most common side effects are mild digestive issues such as fishy burps, which can be reduced by taking capsules with meals or choosing enteric-coated formulations. No serious adverse events were reported in the vast majority of clinical trials reviewed.

Fish Oil vs Algal Oil: The Vegan Alternative

For people who avoid fish products, algal oil (derived from microalgae) provides a plant-based source of preformed EPA and DHA. The critical word here is "preformed", because the body's ability to convert plant-based ALA from flaxseed or walnuts into EPA and DHA is extremely limited.

A randomised double-blind study of 74 adults found that DHA and EPA bioavailability from microalgal oil was statistically non-inferior to fish oil. Separate research confirmed that DHA from algal sources achieves equivalent plasma and red blood cell levels to cooked salmon. For vegans and vegetarians, algal oil with preformed EPA and DHA is the only reliable plant-based option.

Flaxseed oil, chia seeds and walnuts contain ALA (alpha-linolenic acid), a shorter-chain omega-3 that the body must convert to EPA and DHA. This conversion is notoriously inefficient. Studies in dogs have actually shown that plant-based omega-3 sources failed to increase the Omega-3 Index, which dropped from 1.6% to 0.96% after six weeks on flaxseed oil, compared to marine sources which increased it from 1.68% to 2.7% (Dominguez et al., 2021). The same principle applies to humans: if you want the benefits documented in clinical trials, you need preformed EPA and DHA from either fish or algae.

Omega-3 for Dogs

We also stock omega-3 for dogs and cats, and the veterinary evidence supports supplementation for several aspects of canine health. A 2024 study of 29 dogs across five veterinary clinics found that 16 weeks of omega-3 supplementation at 68mg/kg/day significantly increased the Omega-3 Index and reduced pain scores (p=0.012), with benefits most pronounced in small and medium-sized dogs.

Beyond joint health, fish oil supplementation in dogs has been shown to reduce itching and self-trauma while improving coat quality. Cognitive benefits have also been documented, with DHA-supplemented puppies showing increased learning ability and skill retention, and senior dogs with cognitive dysfunction showing improved recognition of family members.

The source of omega-3 matters even more for dogs than humans. Dominguez et al. (2021) demonstrated that marine-sourced omega-3 (krill oil) increased the canine Omega-3 Index from 1.68% to 2.7%, while plant-based flaxseed oil actually caused it to decrease. Dogs, like humans, require preformed EPA and DHA from marine sources rather than plant-based ALA. Browse our full dog health supplement range for complementary products including joint support and probiotics.

Cited Research

• Marchioli R, et al. GISSI-Prevenzione trial: dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. The Lancet. 1999;354:447-455.
• Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine. 2019;380:11-22. doi:10.1056/NEJMoa1812792
• Nicholls SJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258
• Kremer JM, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Arthritis & Rheumatism. 1995;38(8):1107-1114. doi:10.1002/art.1780380813
• Nemets B, et al. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry. 2002;159(3):477-479. doi:10.1176/appi.ajp.159.3.477
• Omega-3 fatty acids and anxiety: a dose-response meta-analysis of 23 randomised trials. BMC Psychiatry. 2024. doi:10.1186/s12888-024-05881-2
• Koch C, et al. Docosahexaenoic acid supplementation in atopic eczema: a randomized, double-blind, controlled trial. British Journal of Dermatology. 2008;158(4):786-792. doi:10.1111/j.1365-2133.2007.08430.x
• Dominguez TE, et al. Omega-3 Index of dogs fed marine vs plant-based lipid sources. Veterinary Medicine and Science. 2021. doi:10.1002/vms3.369